Clinical Trials Logo

Squamous Cell Carcinoma clinical trials

View clinical trials related to Squamous Cell Carcinoma.

Filter by:

NCT ID: NCT05681039 Recruiting - Clinical trials for Squamous Cell Carcinoma

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Start date: June 2, 2023
Phase: Phase 2
Study type: Interventional

To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.

NCT ID: NCT05648604 Recruiting - Melanoma Clinical Trials

Mentored Community Gardening for Individuals With Skin Cancer

H4H2-AZ
Start date: February 2, 2023
Phase: N/A
Study type: Interventional

The investigators will conduct a single-arm pilot feasibility trial of mentored community gardening for melanoma survivors integrating dosimeters and accelerometers. Harvest for Health Together Arizona (H4H2-AZ) is an evidence-based program adapted for arid desert gardening that also addresses sun safety through group workshops and peer education. The primary aim is to evaluate adherence to the intervention.

NCT ID: NCT05574101 Recruiting - Clinical trials for Squamous Cell Carcinoma

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Start date: October 6, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.

NCT ID: NCT05402046 Recruiting - Melanoma (Skin) Clinical Trials

Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms

CAMELLIA
Start date: April 23, 2022
Phase: N/A
Study type: Interventional

A Multicenter, Prospective, Low-interventional Clinical Study Evaluating on mobile application validation ("ProRodinki") in assessing the risk of skin malignant neoplasms

NCT ID: NCT05340543 Recruiting - Melanoma Clinical Trials

Ex-vivo Examination of Excisions of Skin Tumors by Confocal Optical Coherence Tomography (LC-OCT) With Integrated Dermoscopy and Comparison With Histology (DERMOCTAV)

DERMOCTAV
Start date: December 16, 2021
Phase:
Study type: Observational

This project aims to validate ex vivo the use of the OCTAV® prototype integrating the "dermoscope" function before an in vivo application, by comparing images obtained by the OCTAV® prototype integrating the "dermoscope" function with the histological sections of a skin tumor excision corresponding to them exactly, at the same level.

NCT ID: NCT05108090 Recruiting - Clinical trials for Squamous Cell Carcinoma

Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Start date: October 25, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to research if a type of biopsy known as sentinel lymph node biopsy (SLNB) can help in determining the rate of tumor deposits that are hard to detect and identify in node-negative cutaneous squamous cell carcinoma of the head or neck.

NCT ID: NCT05104619 Recruiting - Clinical trials for Squamous Cell Carcinoma

Spectroscopic Analysis of Tongue Tumor Samples.

SpecTum
Start date: October 1, 2021
Phase:
Study type: Observational

In squamous cell carcinoma of the tongue, complete surgical resection of the tumor generally represents the primary treatment strategy. Among factors determining the disease prognostic, the surgical margins status is essential for the continued management of the patient, with or without complementary therapies. Generally, surgical margins are defined using visual and tactile elements. Unfortunately, in 15 to 30 percent of cases, they are defined as positive after histopathological examination, on average 5 to 7 days post-surgery. Techniques have recently been developed to analyze the cancerous and non-cancerous nature of tissues, using the spectral properties of tumor cells. SpiderMass™ is an instrument equipped with a probe for tissue micro-sampling and real-time molecular profile analysis. It is thus ultimately a tool for anatomopathological decision support, for diagnosis and prognosis of the disease. Used in the operating room, SpiderMass™ could also become an innovative surgical tool to precisely define cancerous areas in situ and the margins status in intraoperative conditions. Based on the principle of artificial intelligence, the SpiderMass™ machine must initially learn to recognize pathological tissues versus healthy. This project aims to accomplish this first phase of machine learning for squamous cell carcinoma of the tongue.

NCT ID: NCT05070403 Recruiting - Clinical trials for Squamous Cell Carcinoma

Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.

NCT ID: NCT05048459 Recruiting - Clinical trials for Squamous Cell Carcinoma

Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to compare standard surveillance with telemedicine surveillance (tele-surveillance) and find out which surveillance approach is best for people with HPV-associated head and neck cancer who have no evidence of disease after treatment. The researches will look at how the two approaches affect participants' quality of life, health outcomes, and expenses (for example, costs of routine visits and procedures). They will also determine doctors' and patients' satisfaction with tele-surveillance.

NCT ID: NCT05038657 Recruiting - Clinical trials for Squamous Cell Carcinoma

Atezolizumab Immunotherapy, in Immunotherapy Naive Patients With Urinary Tract Squamous Cell Carcinoma (UTSCC).

AURORA
Start date: May 30, 2022
Phase: Phase 2
Study type: Interventional

Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial